A case report of sequential efgartigimod and rituximab treatment for tSNMG. (PubMed, Front Immunol) - Sep 19, 2026 - "After admission, the patient showed poor responses to treatments including pyridostigmine bromide, human immunoglobulin, glucocorticoids, and tacrolimus. Ultimately, following therapy with efgartigimod followed by rituximab, significant symptomatic improvement was observed. By analyzing the diagnosis and treatment process of this case alongside relevant literature, this report explores the therapeutic value of efgartigimod followed by rituximab for tSNMG, key points for individualized regimen adjustments, and the challenges in diagnosis and treatment, thereby providing a reference for the clinical management of such refractory cases."
Journal • CNS Disorders • Immunology • Myasthenia Gravis • Solid Tumor • Thymoma • Thymus Cancer
|
|
Hua Xie; Lin Zhang; Ting Ting Pan
|